Shots:

• The P-III trials for depemokimab in severe asthma includes SWIFT-1, SWIFT-2 & an OLE AGILE studies. SWIFT-1 & 2 studies evaluate the safety & efficacy as an adjunctive therapy vs PBO in patients (n=375 & n=380) with type 2 inflammation. Another NIMBLE trial is ongoing in patients switching from mepolizumab/benralizumab
• The (SWIFT) trials reached the 1EPs, showing reduced annualized rate of asthma exacerbations over 52wks. with similar incidence & severity of TEAEs b/w depemokimab & PBO. Further analysis is underway to support regulatory submissions & will be highlighted at future conferences
• Depemokimab is an ultra-long-acting biologic that works by binding with high potency to IL-5, a cytokine in type 2 inflammation, allowing 6mos. dosing intervals for severe asthma patients

Ref: GSK | Image: GSK

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com